Reply to “New‐onset bullous pemphigoid after inactivated Covid‐19 vaccine: Synergistic effect of the Covid‐19 vaccine and vildagliptin”

Maronese, Carlo Alberto; Zenzo, Giovanni Di; Genovese, Giovanni; Barei, Francesca; Monestier, Alice; Pira, Anna; Moltrasio, Chiara; Marzano, Angelo Valerio

doi:10.1111/dth.15496

Cited by 10 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…136 Moreover, 40 cases of pemphigoids have been described. [137][138][139][140][141][142][143][144][145][146][147][148][149][150][151] Regarding other cutaneous diseases developed following COVID-19 vaccination, 9, 40, 55, 12 and 11 cases of morphea, [152][153][154][155][156][157] pityriasis rosea, [158][159][160][161][162][163][164][165][166][167][168][169][170][171][172][173][174][175][176][177] herpes zoster, [178][179][180][181][182][183][184]…”

Section: Resultsmentioning

confidence: 99%

“… BNT162b2: 14 mRNA-1273: 4 AZD1222: 6 Ad26.COV2: 0 Pemphigus vulgaris 26 Martora et al 121 (7), Zou et al 122 (3), Gui et al 123 (2), Rouatbi et al 124 (2), Aryanian et al 125 (1), Koutlas et al 126 (1), Knechtl et al 127 (1), Ong et al 128 (1), Yıldırıcı et al 129 (1), Singh et al 130 (1), Norimatsu et al 131 (1), Agharbi et al 132 (1), Almasi-Nasrabadi et al 133 (1), Corrá et al 134 (1), Solimani et al 135 (1). BNT162b2: 15 mRNA-1273: 6 AZD1222: 5 Ad26.COV2: 0 Pemphigoids 40 Maronese et al 137 (21), Maronese et al 138 (3), Hali et al 139 (3), Gambichler et al 140 (2), Shanshal et al 141 (1), Desai et al 142 (1), Fu et al 143 (1), Alshammari et al 144 (1), Hung et al 145 (1), Pauluzzi et al 146 (1), Dell’Antonia et al 147 (1), Pérez-López et al 148 (1), Agharbi et al 149 (1), Young et al 150 (1), Nakamura et al 151 (1). BNT162b2: 29 mRNA-1273: 5 AZD1222: 6 Ad26.COV2: 0 Morphea 9 Paolino et al 152 (4), Antoñanzas et al 153 (2), Oh et al 154 (1), Metin et al 155 (1), Aryanian et al 156 (1).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

show abstract

“…This phenomenon could slightly anticipate BP development without significantly modifying the disease incidence. On the other hand, as some studies reported, it is not unconceivable that COVID-19 vaccines may induce a suitable environment to make these subjects more prone to drug-induced BP, as reported in some case of dipeptidyl peptidase IV inhibitors users (21)(22)(23). Finally, although the meaning of the association between COVID-19 vaccines and AIBDs remains to be elucidated, we hope that Kasperkiewicz and Tukaj speculations, together with our observations, will be able to stimulate the scientific community to design additional investigations on this topic.…”

Section: The Real-life Clinical Observations Are Valuablementioning

confidence: 97%

Response: Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study

et al. 2023

Self Cite

View full text Add to dashboard Cite

“…85 Several cases of anti-SARS-CoV-2 vaccineassociated bullous pemphigoid (BP) have been observed. 86 Maronese et al 87 reported three patients on dipeptidyl peptidase 4 inhibitors (DPPIs) presenting with mild-to moderate BP after vaccination with mRNA COVID-19 Pfizer vaccine. Vildagliptin and sitagliptin (DPPIs) were reported to be associated with new onset BP cases.…”

Section: Anti-diabetic Drugsmentioning

confidence: 99%

Implications of potential clinically relevant interactions between COVID‐19 vaccines and concomitant medications

Badary

2023

Reviews in Medical Virology

View full text Add to dashboard Cite

COVID‐19 was announced as a global pandemic in 2020. Several types of COVID‐19 vaccines are available such as mRNA vaccines, adenovirus vector vaccines, and protein subunit or inactivated virus vaccines. Vaccines are often administered in patients with chronic diseases who are likely to be treated with several drugs. A growing number of clinical observations indicated the possibility of interactions between COVID‐19 vaccines and drugs. A hyperinflammatory state may spark significant imbalances in drug metabolism that may result in the alteration of drug pharmacokinetics and therapeutic response. Furthermore, interactions may result in additive or antagonistic or synergistic vaccine immune response. Information about COVID‐19 vaccine–drug interactions is needed by physicians and pharmacists to make rational drug‐use decisions. In this review, several individual and categorical evidence‐based potential COVID‐19 vaccine–drug interactions of clinical importance are described. Vigilance is needed to detect previously unreported COVID‐19 drug interactions and to further assess known interactions. The clinical significance of which is not fully determined. Evidence suggests that adverse events to some drugs are rare after COVID‐19 vaccination and their possibility should not affect vaccination of patients at risk. Clinicians prescribing medications should be aware of the likely risk of interaction with COVID‐19 vaccines and may benefit from taking into account present recommendations of the best measures to avoid consequences of such interactions to preserve vaccine efficacy and patient safety.

show abstract

Reply to “New‐onset bullous pemphigoid after inactivated Covid‐19 vaccine: Synergistic effect of the Covid‐19 vaccine and vildagliptin”

Cited by 10 publications

References 11 publications

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Response: Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study

Implications of potential clinically relevant interactions between COVID‐19 vaccines and concomitant medications

Contact Info

Product

Resources

About